KK
APGE

KLP Kapitalforvaltning’s Apogee Therapeutics APGE Stock Holding History

KLP Kapitalforvaltning’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.19M Buy
9,000
+1,900
+27% +$171K ﹤0.01% 1023
2026
Q1 		$598K Buy
7,100
+300
+4% +$21.8K ﹤0.01% 1340
2025
Q4 		$513K Buy
6,800
+2,700
+66% +$170K ﹤0.01% 1399
2025
Q3 		$163K Hold
4,100
– – ﹤0.01% 1893
2025
Q2 		$178K Sell
4,100
-900
-18% -$34.2K ﹤0.01% 1832
2025
Q1 		$187K Hold
5,000
– – ﹤0.01% 1774
2024
Q4 		$227K Buy
+5,000
New +$255K ﹤0.01% 1771

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

KLP Kapitalforvaltning's APGE Position: Q2 2026 in Review

KLP Kapitalforvaltning increased its Apogee Therapeutics (APGE) stake by 27% in Q2 2026, buying an estimated $171K and bringing the position to 9,000 shares worth $1.19M. The position accounts for ﹤0.01% of the portfolio, ranked #1023.

KLP Kapitalforvaltning first reported a position in APGE in Q4 2024 and has held it in 7 quarters since. 289 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

  • KLP Kapitalforvaltning held 9,000 shares of Apogee Therapeutics worth $1.19M as of Q2 2026.
  • KLP Kapitalforvaltning bought 1,900 Apogee Therapeutics shares in Q2 2026, an estimated $171K.
  • Apogee Therapeutics made up ﹤0.01% of KLP Kapitalforvaltning's portfolio in Q2 2026, its #1023 holding.
  • KLP Kapitalforvaltning first reported a position in Apogee Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 289 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on KLP Kapitalforvaltning's 13F filing for Q2 2026, filed 12 Aug 2026.